NCT05360953

Treating Nightmares in Posttraumatic Stress Disorder With Clonidine and Doxazosin

Treating Nightmares in Posttraumatic Stress Disorder With the α-adrenergic Agents Clonidine and Doxazosin: A Randomized-Controlled Feasibility Study (ClonDoTrial)

• Status: Suspended
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 53 (actual)
• Sponsor: Charite University, Berlin, Germany · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This randomized controlled trial will test the hypothesis that oral Clonidine or Doxazosin improves nightmares (primary outcome), other PTSD symptoms and psychopathology (secondary outcomes) to a greater extent than placebo over a ten week intervention phase in a parallel group design.

Conditions

• Posttraumatic Stress Disorder

Interventions

Type	Name	Description
DRUG	Clonidine	All patients enrolled establish their individually tolerable dose by dose Titration. Dosage up to a maximum of 0.375 clonidine. Using capsules of 0,075 mg clonidine.
DRUG	Doxazosin	All patients enrolled establish their individually tolerable dose by dose. Dosage up to a maximum of 10 mg doxazosin. Using capsules of 2 mg doxazosin. Titration.
DRUG	Placebo	All patients enrolled establish their individually tolerable dose by dose Titration. Dosage up to a maximum of 5 capsules. Using capsules of placebo.

Timeline

• Start date: 2022-06-17
• Primary completion: 2025-08-08
• Completion: 2026-07-31
• First posted: 2022-05-04
• Last updated: 2025-08-13

Locations

5 sites across 1 country: Germany